• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Medical

CDC survey shows that almost 19 million US adults have asthma

Data from the Centers for Disease Control and Prevention (CDC) Asthma Call-back Survey show that 18.7 million US adults (8.2 percent) have asthma today out of approximately 29.1 million adults (12.7 percent) who have been diagnosed with asthma at some point in their lifetimes. The data are contained in a report called Asthma’s Impact on the Nation. According to the … [Read more...] about CDC survey shows that almost 19 million US adults have asthma

Pulmatrix touts iSPERSE potential for inhaled therapies

Pulmatrix is presenting two posters at RDD, one titled “Formulation Characterization of a Novel Levofloxacin Pulmonary Dry Powder Drug Delivery Technology,” and the other titled “Development of an iSPERSE Based Platform for the Delivery of Macromolecules via Dry Powder Formulations.” The posters include data from in vitro and preclinical studies of formulations … [Read more...] about Pulmatrix touts iSPERSE potential for inhaled therapies

Study confirms ergonomic advantages of Aptar inhaler

Aptar Pharma is presenting results from a clinical study of patient ability to use its Prohaler DPI at RDD this week. The study, which was conducted by Professor Patrice Diot at the Centre Hospitalier Regional Universitaire (CHRU) in Tours, France, demonstrated that all of the asthma and COPD patients involved in the study, no matter how ill, were able to trigger the … [Read more...] about Study confirms ergonomic advantages of Aptar inhaler

Liquidia publishes data from studies of inhalation formulations created with its particle engineering technology

Liquidia Technologies has announced results from two studies of inhalation formulations created using the company’s PRINT (Particle Replication In Non-Wetting Templates) particle engineering technology. One study, published in the 2012 issue of the Journal of Drug Delivery, compared aerodynamic properties of PRINT-zanamivir inhalation powder to Relenza; the other, … [Read more...] about Liquidia publishes data from studies of inhalation formulations created with its particle engineering technology

Pearl reports new data from studies of PT003

Pearl Therapeutics is presenting data from studies of its PT003 metered dose inhaler, glycopyrrolate (GP)/formoterol fumarate (FF) fixed dose combination for the treatment of moderate-to-severe COPD at a number of upcoming meetings. Pearl is also developing MDIs with each of the two component drugs, PT001 (GP) and PT005 (FF). According to the company, one of the … [Read more...] about Pearl reports new data from studies of PT003

Study shows equivalent safety for Symbicort compared to budesonide alone in African Americans

AstraZeneca has announced results of a study showing that the safety profile of Symbicort budesonide/formoterol inhalation aerosol 320/9 µg twice daily was similar to that for a budesonide alone pMDI 320 µg twice daily in African-American patients with moderate-to-severe asthma. The data from the 52-week randomized, double-blind Phase IIIb safety study were published … [Read more...] about Study shows equivalent safety for Symbicort compared to budesonide alone in African Americans

Positive Phase 2 results for nasal spray to treat binge eating disorder

Lightlake Therapeutics has announced preliminary results from a Phase 2 trial of its intranasal naloxone for the treatment of patients with binge eating disorder. According to the company, the randomized, double-blind, placebo-controlled trial demonstrated that patients using the naloxone nasal spray spent a significantly smaller amount of time binge eating than did … [Read more...] about Positive Phase 2 results for nasal spray to treat binge eating disorder

Sunovion to launch Zetonna ciclesonide nasal aerosol in the US by Fall 2012

Sunovion has announced that it will make its Zetonna ciclesonide nasal aerosol for the treatment of allergic rhinitis available in the US in time for the fall allergy season. The FDA approved Zetonna, an HFA formulation delivered by nasal pMDI, in January 2012. Sunovion markets two other ciclesonide aerosols in the US: Omnaris nasal spray for the treatment of … [Read more...] about Sunovion to launch Zetonna ciclesonide nasal aerosol in the US by Fall 2012

Paper compares multi-component particles to mixed powders for inhaled combination therapies

A review paper published in the Spring 2012 issue of European Respiratory Disease contends that, "Drug delivery to lungs with a consistent and predesigned ratio of co-associated active components can help maximise the chance of co-location at the active site and hence increases the potential of synergistic action from the solid." Authored by Dipesh Parikh, David … [Read more...] about Paper compares multi-component particles to mixed powders for inhaled combination therapies

Upsher-Smith recruiting for Phase 3 study of midazolam nasal spray

Upsher-Smith Laboratories is recruiting patients aged 14-65 with partial or generalized epilepsy who experience seizure clusters for an ongoing Phase 3 clinical trial called ARTEMIS1 (Acute Rescue Therapy in Epilepsy with Midazolam Intranasal Spray). As part of the recruiting effort, the company has launched a website, www.seizureclusterstudy.com. Upsher-Smith is … [Read more...] about Upsher-Smith recruiting for Phase 3 study of midazolam nasal spray

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 103
  • Page 104
  • Page 105
  • Page 106
  • Page 107
  • Interim pages omitted …
  • Page 119
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Intertek banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews